Organic compounds

US8163773B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Werner Breitenstein · Basel, CH
• Claus Erhardt · Bad Kötzting, DE
• Juergen Klaus Maibaum · Basel, CH
• Nils Ostermann · Binzen, DE
• Juerg Zimmermann · Reinach, CH
• Keiichi Masuya · Bottmingen, CH
• Kazuhide Konishi · Ibaraki, JP
• Fumiaki Yokokawa · Singapore, SG
• Takanori Kanazawa · Tsukuba, JP
• Edgar Jacoby · Beerse, BE
• Andreas Marzinzik · Weil, DE
• Philipp Grosche · Inzlingen, DE
• Shimpei Kawakami · Tsukuba, JP

Key dates

• Filing date: Jul 10, 2006
• Grant date: Apr 24, 2012
• Expiry date: Feb 22, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The preferred compounds (which can also be present as salts) have the formula I wherein R1, R2, T, R3 and R4 are as defined in the specification.